RxDoctor Payments Data

Karuna Kusan, MD

Infectious Disease · Lawrenceville, GANPI 1013921329

Payments from drug & device makers

$6,580in general payments, 2019–2025

Across 334 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$970
  • Merck$815
  • Melinta Therapeutics, LLC$793
  • Paratek Pharmaceuticals, Inc.$525
  • Insmed, Inc.$473
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$6,34596%
  • Education$2354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,580 in reported general payments places this provider in the 65th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$200,659
Medicare patients
454
Services billed
3,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$167,975
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$158,502
DovatoDolutegravir Sodium/Lamivudine38$122,795
JulucaDolutegravir/Rilpivirine19$71,382
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$49,693
Daptomycin27$28,707
ErtapenemErtapenem Sodium47$23,074
Voriconazole25$19,695
Vancomycin Hcl86$17,095
Meropenem21$6,170
CeftriaxoneCeftriaxone Sodium114$6,004
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam15$5,268
Cefepime Hcl25$4,303
CefuroximeCefuroxime Axetil66$3,524
Doxycycline Hyclate48$1,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$970$326,47778 claims
Viiv Healthcare CompanyDovato, Juluca$1,300$194,17757 claims
Janssen Products, LPSymtuza$31$49,69311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →